Gainers
Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.
IMV Inc (NASDAQ:IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination…
The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed,
IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).
Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023
Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023
IMV Ord Shs (NASDAQ: IMV) shares are trading lower Friday morning after the company announced a $9 million registered direct offering price at-the-market under Nasdaq rules.
What Else?